<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331474</url>
  </required_header>
  <id_info>
    <org_study_id>N06/04/071</org_study_id>
    <nct_id>NCT00331474</nct_id>
  </id_info>
  <brief_title>The Effect of Bacille Calmette Guerin (BCG) Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants</brief_title>
  <official_title>The Effect of BCG Vaccination on Immune Responses in HIV-Exposed and Unexposed Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Stellenbosch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Stellenbosch</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Each year, more than half a million babies are infected with HIV by mother-to child&#xD;
      transmission in developing countries. Many of these babies get sick and develop HIV disease&#xD;
      (AIDS) at a very young age. Exposure to other infectious diseases may influence this early&#xD;
      progression to AIDS. BCG is a live tuberculosis vaccine made from cow tuberculosis. It is&#xD;
      routinely given at birth to most babies, also to babies born to HIV-positive mothers. BCG can&#xD;
      cause disease (BCGosis) in HIV-infected babies. More importantly, BCG may also trigger immune&#xD;
      responses in the body that lead to the spread of the HIV virus and early progression to AIDS.&#xD;
&#xD;
      Objective(s) and Hypothesis:&#xD;
&#xD;
      The researchers will investigate whether BCG causes progression of HIV by doing a clinical&#xD;
      trial: babies born to HIV-positive mothers will be randomly allocated to get the BCG vaccine&#xD;
      at birth or at 14 weeks of age. In these 2 groups of babies, the researchers will compare:&#xD;
&#xD;
        -  The percentage of babies who progress to HIV disease&#xD;
&#xD;
        -  Blood markers of HIV disease (the amount of virus and protective white blood cells in&#xD;
           the body)&#xD;
&#xD;
        -  The body's immune response to BCG vaccine and other childhood vaccines&#xD;
&#xD;
        -  The percentage of children who develop BCG scarring, BCG vaccine complications and&#xD;
           tuberculosis.&#xD;
&#xD;
      Potential Impact:&#xD;
&#xD;
      BCG is the most widely given vaccine worldwide and is routinely given to babies born to&#xD;
      HIV-positive mothers in developing countries. Any effect that BCG has on HIV progression in&#xD;
      babies will have a significant public health impact in settings with a high burden of HIV&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BCG-induced cellular immune responses</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BCG scarring</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum antibody responses</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tuberculosis incidence</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">180</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG delayed</intervention_name>
    <description>early (birth) and delayed (14 weeks) intradermal BCG vaccination</description>
    <other_name>early vs. delayed BCG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Maternal HIV status verified&#xD;
&#xD;
          -  Study consent&#xD;
&#xD;
          -  Uncomplicated singleton pregnancy with delivery planned at local health facility&#xD;
&#xD;
          -  Resident in study area&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active tuberculosis or tuberculosis contact in mother&#xD;
&#xD;
          -  No consent&#xD;
&#xD;
          -  Planning to move out of study area&#xD;
&#xD;
          -  Not planning on delivering at local maternal obstetric unit&#xD;
&#xD;
          -  Not planning on attending local baby clinic&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>48 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anneke C Hesseling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Desmond Tutu TB Centre, Dept. Pediatrics and Child Health, Stellenbosch University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Desmond Tutu TB Centre</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape Province</state>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>May 30, 2006</study_first_submitted>
  <study_first_submitted_qc>May 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2006</study_first_posted>
  <last_update_submitted>February 13, 2009</last_update_submitted>
  <last_update_submitted_qc>February 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Esther Steyn or Liesel Strauss</name_title>
    <organization>Stellenbosch University</organization>
  </responsible_party>
  <keyword>BCG</keyword>
  <keyword>HIV</keyword>
  <keyword>Immune responses</keyword>
  <keyword>Delayed vaccination</keyword>
  <keyword>Infant morbidity</keyword>
  <keyword>Nutritional status</keyword>
  <keyword>Morbidity</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

